Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Horizon Pharma PLC is a drug manufacturers-general business based in the US. Horizon Pharma shares (HZNP) are listed on the NASDAQ and all prices are listed in US Dollars. Horizon Pharma employs 1,940 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $80.84 |
|---|---|
| 52-week range | $78.75 - $120.54 |
| 50-day moving average | $89.88 |
| 200-day moving average | $100.89 |
| Wall St. target price | $137.57 |
| PE ratio | 22.3315 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $3.62 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $80.84 from 2022-07-01
| 1 week (2022-06-28) | -1.04% |
|---|---|
| 1 month (2022-06-06) | -7.31% |
| 3 months (2022-04-06) | -25.80% |
| 6 months (2022-01-06) | -17.32% |
| 1 year (2021-07-06) | -15.60% |
|---|---|
| 2 years (2020-07-06) | 39.12% |
| 3 years (2019-07-05) | 231.99% |
| 5 years (2017-07-05) | 546.72% |
Valuing Horizon Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Horizon Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Horizon Pharma's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Horizon Pharma shares trade at around 22x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Horizon Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Horizon Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Horizon Pharma's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $973.4 million.
The EBITDA is a measure of a Horizon Pharma's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $3.8 billion |
|---|---|
| Operating margin TTM | 25.32% |
| Gross profit TTM | $2.5 billion |
| Return on assets TTM | 7.19% |
| Return on equity TTM | 19.88% |
| Profit margin | 22.87% |
| Book value | $20.99 |
| Market capitalisation | $18.6 billion |
TTM: trailing 12 months
We're not expecting Horizon Pharma to pay a dividend over the next 12 months.
Over the last 12 months, Horizon Pharma's shares have ranged in value from as little as $78.75 up to $120.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Horizon Pharma's is 1.1211. This would suggest that Horizon Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC. ; Alpine Immune Sciences, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.